Related Experiment Video
Updated: May 6, 2026
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
TNF-α blockade is ineffective in animal models of established polycystic kidney disease
1Biomed Valley Discoveries Inc, 4520 Main Street, Suite 1650, MO 64111, Kansas City, USA. ssaha@biomed-valley.com.
Background:
Given the large medical burden of polycystic kidney disease (PKD) and recent clinical trial failures, there is a need for novel, safe and effective treatments for the disorder.
Methods:
In PCK rat and PKD2(ws25/w183) mouse models, entanercept was administered once every three days at 5 or 10 mg/kg, once daily. Mozavaptan was administered as a pilot control, provided continuously via milled chow at 0.1%. Animals were assessed for measures of pharmacodynamic response, and improvements in measures of polycystic kidney disease.
Results:
Entanercept treatment modulated inflammatory markers, but provided limited therapeutic benefit in multiple animal models of established polycystic kidney disease. Kidney weight, cyst burden and renal function markers remained unchanged following administration of etanercept at various dose levels and multiple treatment durations.
Conclusions:
While it remains possible that TNF-α inhibition may be effective in truly preventative settings, our observations suggest this pathway is less likely to exhibit therapeutic or disease-modifying efficacy following the standard clinical diagnosis of disease.
Insights
Etanercept showed limited benefit for polycystic kidney disease (PKD) in animal models, failing to improve kidney weight, cyst burden, or function. This suggests TNF-α inhibition may not be effective for established PKD.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Polycystic kidney disease (PKD) poses a significant medical burden.
- Recent clinical trials for PKD treatments have faced failures.
- Novel therapeutic strategies for PKD are urgently needed.
Purpose of the Study:
- To evaluate the efficacy of etanercept, a TNF-α inhibitor, in preclinical models of polycystic kidney disease.
- To assess the therapeutic potential of targeting inflammation in established PKD.
Main Methods:
- Etanercept was administered to PCK rat and PKD2(ws25/w183) mouse models.
- Different dosages and treatment durations of etanercept were tested.
- Mozavaptan served as a pilot control.
Main Results:
- Etanercept modulated inflammatory markers but offered minimal therapeutic benefit in established PKD models.
- No significant changes were observed in kidney weight, cyst burden, or renal function markers.
- These findings indicate limited efficacy of etanercept in treating established polycystic kidney disease.
Conclusions:
- TNF-α inhibition may hold potential in preventative settings for PKD.
- The current study suggests TNF-α inhibition is unlikely to be therapeutically effective for established PKD.
- Targeting inflammation might not be a viable strategy for disease modification in diagnosed PKD patients.
More Related Videos
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
